<DOC>
	<DOCNO>NCT00284947</DOCNO>
	<brief_summary>The long-term use calcineurin inhibitor ( CNI ) patient receive kidney transplantation associate renal dysfunction hypertension . The study evaluate safety efficacy replace calcineurin inhibitor use basiliximab monthly dos .</brief_summary>
	<brief_title>Safety Efficacy Basiliximab Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid Steroids</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Patients first kidney transplant living decease donor least 12 month transplantation . Patients receive CNI , mycophenolic acid ( MPA ) oral corticosteroid . Patients able tolerate full dose MPA . Patients glomerular filtration rate ( GFR ) &gt; 30 mL/min . Patients without acute rejection episode precede 6 month . Patients sign symptom CNI intolerance ( renal dysfunction , poor blood pressure control , diabetes , poor lipid control , hyperuricemia gout , significant hypophosphatemia hypomagnesemia , gingival hyperplasia , hypertrichosis , etc . ) CNI interruption justify . Patients preform positive skin test basiliximab Patients preform panel reactive antibody ( PRA ) &gt; 10 % . Signs active immune process graft biopsy . Patients multiorgan second kidney transplant Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Side effect</keyword>
	<keyword>calcineurin inhibitor</keyword>
	<keyword>maintenance</keyword>
	<keyword>basiliximab</keyword>
	<keyword>Kidney maintenance transplant</keyword>
</DOC>